The Spanish group Grifols is a benchmark company in blood products (a pharmaceutical specialty whose active ingredient originates from the blood of healthy donors) with a solid international track record. In 2018, the company's turnover reached € 4,487MM with an EBITDA of € 1,215MM (EBITDA Margin of 27%). NFD/EBITDA ratio stood at 4.3x.
Date last rating: 07/25/2019
Date first rating: 07/26/2018